NCT05574985View on ClinicalTrials.gov

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

NACompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

October 9, 2022

Study Completion Date

March 18, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

Injected one dose of research vaccine

BIOLOGICAL

Inactivated COVID-19 vaccine (Vero Cell)

Injected one dose of control vaccine

Trial Locations (1)

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

All Listed Sponsors
collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY